Display options
Cite
Bush SH, Tollin S, Marchion DC, et al. Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Mol Clin Oncol. 2016;4(3):399-404doi: 10.3892/mco.2016.725.
Bush, S. H., Tollin, S., Marchion, D. C., Xiong, Y., Abbasi, F., Ramirez, I. J., Zgheib, N. B., Boac, B., Judson, P. L., Chon, H. S., Wenham, R. M., Apte, S. M., Cubitt, C. L., Berglund, A. E., Havrilesky, L. J., & Lancaster, J. M. (2016). Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Molecular and clinical oncology, 4(3), 399-404. https://doi.org/10.3892/mco.2016.725
Bush, Stephen H, et al. "Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival." Molecular and clinical oncology vol. 4,3 (2016): 399-404. doi: https://doi.org/10.3892/mco.2016.725
Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM. Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival. Mol Clin Oncol. 2016 Mar;4(3):399-404. doi: 10.3892/mco.2016.725. Epub 2016 Jan 07. PMID: 26998291; PMCID: PMC4774474.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2016 Mar;4(3):399-404. doi: 10.3892/mco.2016.725. Epub 2016 Jan 07.

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Molecular and clinical oncology

Stephen H Bush, Sharon Tollin, Douglas C Marchion, Yin Xiong, Forough Abbasi, Ingrid J Ramirez, Nadim Bou Zgheib, Bernadette Boac, Patricia L Judson, Hye Sook Chon, Robert M Wenham, Sachin M Apte, Christopher L Cubitt, Anders E Berglund, Laura J Havrilesky, Johnathan M Lancaster

Affiliations

  1. Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  2. Translational Research Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  3. Cancer Informatics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  4. Duke University Medical Center, Durham, NC 27710, USA.

PMID: 26998291 PMCID: PMC4774474 DOI: 10.3892/mco.2016.725

Abstract

Experimental and epidemiological data support the potential activity of acetaminophen against ovarian cancer (OVCA). In this study, we sought to confirm the activity of acetaminophen in OVCA cell lines and to investigate the molecular basis of response. A total of 16 OVCA cell lines underwent pretreatment (baseline) genome-wide expression measurements and were then treated with and analyzed for acetaminophen sensitivity. Pearson's correlation analysis was performed to identify genes that were associated with OVCA acetaminophen response. The identified genes were subjected to pathway analysis, and the expression of each represented pathway was summarized using principal component analysis. OVCA acetaminophen response pathways were analyzed in 4 external clinico-genomic datasets from 820 women for associations with overall survival from OVCA. Acetaminophen exhibited antiproliferative activity against all tested OVCA cell lines, with half maximal inhibitory concentration values ranging from 63.2 to 403 µM. Pearson's correlation followed by biological pathway analysis identified 13 pathways to be associated with acetaminophen sensitivity (P<0.01). Associations were observed between patient survival from OVCA and expression of the following pathways: Development/angiotensin signaling via β-arrestin (P=0.04), protein folding and maturation/angiotensin system maturation (P=0.02), signal transduction/c-Jun N-terminal kinase (JNK) pathway (P=0.03) and androstenedione and testosterone biosynthesis and metabolism (P=0.02). We confirmed that acetaminophen was active against OVCA cells

Keywords: acetaminophen; c-Jun N-terminal kinase pathway; molecular signaling pathways; ovarian cancer; paracetamol

References

  1. Anticancer Res. 2013 Jun;33(6):2391-400 - PubMed
  2. Cancer Res. 2008 Jul 1;68(13):5031-9 - PubMed
  3. J Int Med Res. 1976;4(4 Suppl):1-6 - PubMed
  4. Clin Cancer Res. 2002 Jan;8(1):202-9 - PubMed
  5. Biochim Biophys Acta. 2007 Aug;1773(8):1341-8 - PubMed
  6. Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):903-6 - PubMed
  7. Breast Cancer Res Treat. 2010 Jan;119(2):335-46 - PubMed
  8. J Biol Chem. 2003 May 23;278(21):19245-56 - PubMed
  9. J Natl Cancer Inst. 2014 May 21;106(6):dju111 - PubMed
  10. Curr Opin Cell Biol. 2007 Apr;19(2):142-9 - PubMed
  11. Clin Cancer Res. 2011 Oct 1;17(19):6356-66 - PubMed
  12. Semin Liver Dis. 2007 Nov;27(4):378-89 - PubMed
  13. N Engl J Med. 1996 Jan 4;334(1):1-6 - PubMed
  14. Clin Infect Dis. 2000 Oct;31 Suppl 5:S202-10 - PubMed
  15. Clin Cancer Res. 2008 Aug 15;14(16):5198-208 - PubMed
  16. J Clin Oncol. 2003 Sep 1;21(17):3194-200 - PubMed
  17. Antioxid Redox Signal. 2009 Sep;11(9):2245-63 - PubMed
  18. Gastroenterology. 2006 Jul;131(1):165-78 - PubMed
  19. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  20. Clin Cancer Res. 2010 Jan 1;16(1):184-94 - PubMed
  21. Ann Intern Med. 1977 Aug;87(2):202-9 - PubMed
  22. Epidemiology. 2012 Mar;23(2):311-9 - PubMed
  23. J Biol Chem. 2011 Oct 7;286(40):35071-8 - PubMed
  24. Am J Epidemiol. 2008 Jun 15;167(12):1430-7 - PubMed
  25. Lancet. 1998 Jan 10;351(9096):104-7 - PubMed

Publication Types

Grant support